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ABSTRACT
In order to examine secular changes in the incidence and mortality associated with Staphylococcus aureus
bacteraemia before and after the emergence of methicillin-resistant S. aureus (MRSA), a retrospective
cohort study of 815 patients with S. aureus bacteraemia was performed in the Estrie region of Quebec,
Canada, between 1991 and 2005. The primary outcome was all-cause 30-day mortality. Between 1991–
1993 and 2003–2005, the proportion of cases attributed to endocarditis and pneumonia increased from
4% to 11% and from 2% to 11%, respectively, while that attributed to catheter infections decreased from
49% to 17%. MRSA was almost absent in 1991–1999, but accounted for 10% and 20% of cases in 2000–
2002 and 2003–2005, respectively. The population incidence of bacteraemia caused by methicillin-
susceptible S. aureus (MSSA) remained stable between 1997 and 2005, while that of MRSA increased
from 0 to 7.4/100 000. Risk-factors for mortality included age, co-morbidities, female gender, residence
outside the city of Sherbrooke, pneumonia (OR 3.35, 95% CI 1.96–5.73) or endocarditis (OR 2.89,
95% CI 1.67–5.01) as the source, and an absence of treatment. After adjusting for confounders, patients
with MRSA bacteraemia had a higher mortality rate than those with MSSA bacteraemia (OR 2.21,
95% CI 0.99–4.96, p 0.053). Mortality in patients with MSSA bacteraemia was 19% (16/83) in 1991–1993,
23% (26/113) in 1994–1996, 29% (50/173) in 1997–1999, and 28% (52/185) in 2000–2002, decreasing to
15% (28/192) in 2003–2005, which impacted on the relative mortality rates of MRSA and MSSA. MRSA
did not replace, but added to, an existing stable incidence of MSSA bacteraemia.
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INTRODUCTION
The relentless progression of methicillin-resistant
Staphylococcus aureus (MRSA), especially within
intensive care units, is causing considerable con-
cern, given that empirical regimens for sepsis may
not always cover MRSA, and that vancomycin is
generally considered to be a sub-optimal anti-
staphylococcal agent [1–4]. In the UK, the pro-
portion of MRSA isolates from bacteraemic
patients rose from 2% in 1990 to c. 40% in the
early 2000s [3], with corresponding proportions of
>30% in France, Italy, Greece and Ireland, but
<1% in The Netherlands and Scandinavia [5]. In
Canada, the proportion of MRSA among S. aureus
isolates is also heterogeneous, with the highest
prevalence being in Quebec, where 27% of blood
culture S. aureus isolates in 2005 were methicillin-
resistant [6]. The traditional distinction between
community-acquired and hospital-acquired
S. aureus bacteraemia (SAB) has become blurred,
with many cases that were diagnosed within 48 h
of admission, but involved other exposures to the
healthcare system within the previous year, now
being considered to be ‘healthcare-associated’
[7,8].
The question of whether MRSA is associated
with a higher mortality rate than methicillin-
susceptible S. aureus (MSSA) remains controver-
sial, and little is known about the impact of
antimicrobial resistance on the incidence of
disease in hospitals and the community. To
delineate secular changes among patients with
SAB, and especially the impact of the emergence
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of methicillin resistance on the population inci-
dence of SAB and its outcomes, a retrospective
cohort study of patients diagnosed with SAB in
a secondary/tertiary-care hospital in Canada
between 1991 and 2005 was performed.
MATERIALS AND METHODS
Setting and study population
The Centre Hospitalier Universitaire de Sherbrooke (CHUS)
provides all necessary hospital care to the 148 300 inhabitants
of Sherbrooke, and most (but not all) hospital care for the
inhabitants of the rest of the Estrie region (total population
296 700) in southern Quebec, as well as tertiary care to a larger
catchment population. The study population comprised all
patients aged ‡18 years with at least one blood culture positive
for S. aureus between January 1991 and December 2005 at the
CHUS Hoˆpital-Fleurimont, and between January 1997 and
December 2005 at the CHUS Hoˆtel-Dieu. The latter became
part of the CHUS at the end of 1996; it was not possible before
this merger to retrospectively identify cases of SAB docu-
mented by the Hoˆtel-Dieu’s microbiology laboratory, or in two
other Sherbrooke hospitals that were transformed at this time
into long-term care facilities. However, from 1997 onwards,
when there was high conﬁdence of having captured nearly all
cases among residents of Sherbrooke, hospital data could be
translated into measures of population incidence. In total, 826
episodes of SAB were identiﬁed in 792 patients from the
computerised hospital records system and a registry of
positive blood cultures. Eleven patients, for whom the attend-
ing physicians had considered the positive blood culture to be
a contaminant (i.e., only one blood culture positive, no source
of infection found, no treatment initiated, no complications
and survival), were excluded, leaving 815 episodes of bacter-
aemia for analysis. For any given patient, two positive blood
cultures separated by ‡3 months were considered to be
different events and were analysed separately. The primary
outcome was all-cause mortality within 30 days of the onset of
bacteraemia.
Data collection and deﬁnitions
Permission to audit the records for retrospective data collec-
tion was given by the CHUS according to institutional
policies. Data collected included demographical characteris-
tics, past medical history (to calculate the Charlson weighted
index of co-morbidities) [9], immune status, anatomical sites
of S. aureus infection, whether S. aureus infection was hospi-
tal-, healthcare- or community-acquired, sensitivity to oxacil-
lin, antibiotics administered within 14 days of the ﬁrst
positive blood culture, and the presence of shock. A bacter-
aemia was considered to be: (i) hospital-acquired if it
occurred >48 h after hospital admission or within 14 days
of discharge; (ii) healthcare-associated if the previous deﬁni-
tion was not applicable, but the patient had been hospitalised
for ‡24 h or resided in long-term care facilities in the past
year, or had undergone outpatient surgery, received dialysis
or cancer chemotherapy, or had an intravenous catheter or
some other device (nephrostomy, ileostomy, colostomy, blad-
der catheter, biliary drain) used at home; or (iii) community-
acquired in all other cases. The discharge diagnoses recorded
in the summary form for relevant hospital admissions were
used to delineate the anatomical sites of infection. Immuno-
suppression was deﬁned as the use of immunosuppressive
drugs or systemic corticosteroids for ‡1 month, existence of
neutropenia (<1000/lL), organ transplant, human immuno-
deﬁciency virus infection, leukaemia or lymphoma. Shock
was recorded if vasopressors had been administered. Effec-
tive treatment was deﬁned as the administration of an
antibiotic to which the infecting organism was susceptible,
with the main treatment being the antibiotic given for ‡7 of
the ﬁrst 14 days or, for patients who died within this period,
the antibiotic given for at least half the interval between the
onset of bacteraemia and death. The period of observation
was divided into ﬁve 3-year periods.
Blood culture systems used were, successively, the BAC-
TEC NR730, BACTEC 9120 and BACTEC 9240 systems
(Becton Dickinson, Franklin Lakes, NJ, USA). Gram-positive
catalase-positive cocci were identiﬁed as S. aureus if they
yielded a positive slide coagulase test for clumping factor.
A negative slide coagulase test was conﬁrmed by a tube
coagulase test. Isolates found to be oxacillin-resistant or
intermediately-resistant according to a Kirby–Bauer disk-dif-
fusion assay (£12 mm) were further investigated using Etests
(AB Biodisk, Solna, Sweden) on Mueller–Hinton agar contain-
ing NaCl 2% w/v to determine their oxacillin MIC. Isolates
with an MIC of ‡4 mg/L were considered to be MRSA. From
April 2003, MRSA isolates were also conﬁrmed by identiﬁca-
tion of the mecA gene using PCR (LightCycler; Roche,
Pleasanton, CA, USA).
Statistical analysis
Proportions were compared using the chi-square test. ORs and
95% CIs were calculated using logistic regression with Stata
software v.8.0 (Stata Corp., College Station, TX, USA). Multi-
variate models were built sequentially, starting with the
variable associated most strongly with the outcome, and
continuing until no other variable reached signiﬁcance. When
the ﬁnal model was reached, each variable was dropped in
turn to assess its effect, with different models being compared
using the likelihood ratio test. The ﬁnal model retained
variables that signiﬁcantly enhanced the ﬁt at the p £0.05
level. Shock was not included within the multivariate model
because it was related too closely to the outcome. Interactions
were sought between selected variables.
RESULTS
Patient characteristics
The median age of the patients was 66 years
(inter-quartile range: 54–75 years); 509 (62%)
were male. Bacteraemia was considered to be
hospital-acquired in 491 (60%) cases and health-
care-associated in 207 (25%) cases. The Charlson
index was >3 for 428 (53%) patients, and 167
(20%) patients were immunosuppressed. As
shown in Table 1, the geographical origins of
patients showed little variation after 1993, and the
distribution of Charlson scores remained stable.
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MRSA was very uncommon between 1991 and
1999, but then emerged and was isolated in 69
(8.5%) cases. There were important secular
changes in the sources of SAB, with substantial
decreases in the proportion of cases caused by
catheter sepsis and/or septic phlebitis, while the
proportion of cases attributed to endocarditis,
pneumonia and urinary tract infections increased.
The proportion of patients who had a trans-
oesophageal echocardiogram increased from 2%
(2/85) in 1991–1993 to 23% (54/239) in 2003–2005.
The proportion of patients who received effective
treatment within the ﬁrst 24 h showed little
change over time; vancomycin was used in 80%
of MRSA cases (data not shown). In cases of
MSSA bacteraemia, the use of cefazolin as the
main treatment within the ﬁrst 14 days doubled
over time.
Compared with patients with MSSA bactera-
emia, those with MRSA bacteraemia were older,
had a higher Charlson score, and were less likely
to have received an effective antibiotic within the
ﬁrst 24 h (Table 2). There were few differences
with respect to the sources of infection, with the
exception of the urinary tract (more common with
MRSA) and catheter infections (more common
with MSSA). The only patient with community-
acquired MRSA bacteraemia was an American
visitor who died of endocarditis on the day of
admission, and for whom there was minimal
information concerning past medical history.
Treatment and outcome
Overall, 24% (195/815) of patients died within
30 days of the onset of SAB. Table 3 summarises
Table 1. Characteristics of patients (%) with Staphylococcus aureus bacteraemia 1991–2005, grouped according to the year of
diagnosis
1991–1993 (n = 85) 1994–1996 (n = 113) 1997–1999 (n = 173) 2000–2002 (n = 205) 2003–2005 (n = 239) p value
Age (years)
18–64 47 (55) 51 (45) 70 (40) 88 (43) 104 (44) 0.29
65–74 25 (29) 35 (31) 48 (28) 59 (29) 70 (29)
‡75 13 (15) 27 (24) 55 (32) 58 (28) 65 (27)
Gender
Male 56 (66) 67 (59) 107 (62) 140 (68) 139 (58) 0.21
Female 29 (34) 46 (41) 66 (38) 65 (32) 100 (42)
Residence
Sherbrooke 22 (26) 50 (44) 80 (46) 90 (44) 114 (48) 0.02
Estrie region other than Sherbrooke 37 (44) 42 (37) 64 (37) 82 (40) 90 (38)
Outside Estrie region 26 (31) 21 (19) 29 (17) 33 (16) 35 (15)
Acquisition
Community 8 (9) 8 (7) 32 (18) 31 (15) 38 (16) <0.001
Healthcare-associated 29 (34) 12 (6) 36 (21) 53 (26) 77 (32)
Hospital 48 (56) 93 (82) 105 (61) 121 (59) 124 (52)
Charlson co-morbidity score
0 7 (8) 14 (12) 23 (13) 26 (13) 15 (6) 0.16
1–3 34 (40) 42 (37) 71 (41) 69 (34) 86 (36)
‡4 44 (52) 57 (50) 79 (46) 110 (54) 138 (58)
Immunosuppression
No 66 (78) 90 (80) 136 (79) 155 (76) 201 (84) 0.26
Yes 19 (22) 23 (20) 37 (21) 50 (24) 38 (16)
Type of infectiona
Endocarditis 3 (4) 6 (5) 22 (13) 32 (16) 27 (11) 0.008
Pneumonia 2 (2) 6 (5) 20 (12) 24 (12) 27 (11) 0.04
Catheter infections/septic phlebitis 42 (49) 53 (47) 60 (35) 58 (28) 40 (17) <0.001
Mediastinitis/other endovascular 13 (15) 26 (23) 28 (16) 22 (11) 31 (13) 0.05
Surgical wound/bone/soft-tissue 21 (25) 26 (23) 44 (25) 65 (32) 69 (29) 0.40
Urinary tract 4 (5) 3 (3) 6 (4) 13 (6) 27 (11) 0.005
Other/indeterminate 8 (9) 8 (7) 15 (9) 16 (8) 25 (10) 0.83
Antibiotic susceptibility
Methicillin-susceptible 83 (98) 113 (100) 173 (100) 185 (90) 192 (80) <0.001
Methicillin-resistant 2 (2) 0 (0) 0 (0) 20 (10) 47 (20)
Shock
No 77 (91) 96 (85) 143 (83) 172 (84) 196 (82) 0.44
Yes 8 (9) 17 (15) 30 (17) 33 (16) 43 (18)
Main treatment, ﬁrst 14 daysb
Cloxacillin 31 (37) 65 (58) 91 (53) 69 (37) 88 (46) 0.001
Cefazolin 9 (11) 18 (16) 24 (14) 39 (21) 43 (22) 0.06
Vancomycin 10 (12) 7 (6) 10 (6) 10 (5) 11 (6) 0.33
Other antibiotic 13 (16) 12 (11) 23 (13) 26 (14) 25 (13) 0.89
Multiple antibiotics 17 (20) 10 (9) 21 (12) 36 (19) 22 (11) 0.03
No antibiotic 3 (4) 1 (1) 4 (2) 5 (3) 3 (2) 0.68
aMore than one site was identiﬁed in some patients.
bMethicillin-susceptible S. aureus only.
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the factors associated with 30-day mortality in
univariate and multivariate analyses. The 30-day
mortality rate increased to 29% in 1997–1999, but
then decreased to 18% in 2003–2005. Restricting
the analysis to patients with MSSA bacteraemia,
30-day mortality was 19% in 1991–1993, 23% in
1994–1996, 29% in 1997–1999, 28% in 2000–2002,
but only 15% in 2003–2005. The difference in
mortality between MRSA and MSSA infections
occurred essentially in 2003–2005, when 34% of
MRSA patients died.
As expected, mortality increased with age.
Although males outnumbered females, mortality
was higher among women. Mortality increased
with the Charlson index (Charlson 0, 14% (12/85);
Charlson 1–3, 17% (52/302); Charlson ‡4, 31%
(131/428), p <0.001) and was higher in immuno-
suppresssed patients (34%, 57/168) than in immu-
nocompetent patients (21%, 138/649) (p <0.001).
Table 3 also shows the speciﬁc medical conditions
associated with 30-day mortality. Mortality was
similar whether SAB was hospital-acquired (25%,
123/491), healthcare-associated (22%, 46/207) or
community-acquired (22%, 26/117) (p 0.65). The
30-day mortality rate was highest in patients with
pneumonia or endocarditis, reaching 44% and
38%, respectively, and among patients with an
unknown source of infection (37%); lower rates
were seen for other anatomical sources of infec-
tion, ranging from 15% for bone/soft-tissue infec-
tions to 22% for catheter-related infections and/or
septic phlebitis, and mediastinitis or other endo-
vascular infections, which were grouped for the
multivariate analysis. Although patients with
MRSA bacteraemia received adequate antibiotics
within the ﬁrst 24 h less frequently, this did not
impact on outcome. Mortality did not vary accord-
ing to the main antibiotic used during the ﬁrst
2 weeks for either the whole group or the sub-
group of patients with pneumonia (data not
shown).
In multivariate analysis, independent predic-
tors of mortality were an age ‡65 years, female
gender, residence outside the city of Sherbrooke,
co-morbidities (chronic renal failure, liver disease,
lymphoma, metastatic cancer, connective tissue
disease), an absence of treatment, the anatomical
site of infection and, with borderline signiﬁcance
(p 0.053), methicillin resistance. Mortality was
signiﬁcantly lower in patients diagnosed in
2003–2005 compared with 1997–1999. After
adjustment for these confounders, hospital acqui-
sition, effective treatment within the ﬁrst 24 h,
immune status and other co-morbidities included
in the Charlson score were not associated signif-
icantly with mortality.
To further investigate secular changes in mor-
tality, subgroup analyses were conducted. Com-
pared to the reference period (1997–1999),
mortality in 2003–2005 was lower in patients with
hospital/healthcare-acquired infections (OR 0.48,
95% CI 0.29–0.80, p 0.005), but not in patients
with community-acquired SAB (OR 1.16,
95% CI 0.35–3.77, p 0.81), and was lower in
patients with (OR 0.38, 95% CI 0.14–0.99,
p 0.048) and without (OR 0.58, 95% CI 0.33–1.02,
p 0.06) shock. The reduction in mortality was
signiﬁcant for patients with pneumonia (OR 0.15,
95% CI 0.05–0.51, p 0.002), but not for patients
with endocarditis (OR 0.71, 95% CI 0.22–2.22,
p 0.55) or infections at other sites (OR 0.74,
95% CI 0.41–1.35, p 0.33). The reduction in mor-
tality occurred essentially in patients with MSSA
bacteraemia (OR 0.42, 95% CI 0.25–0.71, p 0.001).
Table 2. Characteristics of patients (%) with methicillin-
resistant and methicillin-susceptible Staphylococcus aureus
bacteraemia
Characteristic
Methicillin-susceptible
S. aureus
(n = 746)
Methicillin-resistant
S. aureus
(n = 69) p valuea
Age (years)
18–64 339 (45) 21 (30) 0.02
65–74 208 (28) 29 (42)
‡75 199 (27) 19 (28)
Gender
Male 467 (63) 42 (61) 0.88
Female 279 (37) 27 (39)
Acquisition
Community 116 (16) 1 (1) 0.004
Healthcare-associated 184 (25) 23 (33)
Hospital 446 (60) 45 (65)
Charlson score
0 80 (11) 5 (7) 0.01
1–3 286 (38) 16 (23)
‡4 380 (51) 48 (70)
Immunosuppression
No 597 (80) 51 (74) 0.29
Yes 149 (20) 18 (26)
Type of infectionb
Endocarditis 81 (11) 9 (13) 0.72
Pneumonia 71 (10) 8 (12) 0.72
Catheter infections/
septic phlebitis
240 (32) 13 (19) 0.03
Mediastinitis/other
endovascular
109 (15) 11 (16) 0.90
Surgical wound/bone/
soft-tissue
210 (28) 15 (22) 0.32
Urinary tract 42 (6) 11 (16) 0.003
Other/indeterminate 63 (8) 9 (13) 0.28
Shock
No 629 (84) 55 (80) 0.41
Yes 117 (16) 14 (20)
Effective treatment in ﬁrst 24 h
Yes 575 (77) 33 (48) <0.001
No 171 (23) 36 (52)
aChi-square or Fisher’s test if expected values were <5.
bSome patients had more than one site identiﬁed.
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Incidence
The incidence of SAB in residents of the city of
Sherbrooke increased by 34% between 1997–1999
and 2003–2005 (Table 4), corresponding to a
stable incidence of MSSA bacteraemia to which
the incidence of MRSA bacteraemia was progres-
sively added. The incidence of SAB increased
dramatically with age.
DISCUSSION
The question of whether MRSA bacteraemia is
associated with a higher rate of mortality than
Table 3. Risk-factors for 30-day mortality among patients with Staphylococcus aureus bacteraemia, 1991–2005
Characteristic Death within 30 days/total (%) OR (95% CI) Adjusted OR (95% CI)
Year of diagnosis
All patients
1991–1993 17/85 (20) 0.62 (0.33–1.15) 0.66 (0.31–1.37)
1994–1996 26/113 (23) 0.74 (0.43–1.27) 0.91 (0.48–1.71)
1997–1999 50/173 (29) 1.00 1.00
2000–2002 58/205 (28) 0.97 (0.62–1.52) 0.77 (0.45–1.31)
2003–2005 44/239 (18) 0.56 (0.35–0.88)a 0.44 (0.25–0.77)a
Methicillin-susceptible only
1991–1993 16/83 (19)
1994–1996 26/113 (23)
1997–1999 50/173 (29)
2000–2002 52/185 (28)
2003–2005 28/192 (15)
Methicillin-resistant only
1991–1993 1/2 (50)
1994–1996 0/0
1997–1999 0/0
2000–2002 6/20 (30)
2003–2005 16/47 (34)
Age (years)
18–64 51/360 (14) 1.00 1.00
65–74 63/237 (27) 2.19 (1.45–3.32)b 2.31 (1.43–3.73)b
‡75 81/218 (37) 3.58 (2.39–5.37)b 4.34 (2.68–7.03)b
Gender
Male 110/509 (22) 1.00 1.00
Female 85/306 (28) 1.40 (1.01–1.94)a 1.59 (1.09–2.34)a
Residence
Sherbrooke 77/356 (22) 1.00 1.00
Estrie 88/315 (28) 1.40 (0.99–2.00) 1.76 (1.16–2.67)a
Other 30/144 (21) 0.95 (0.59–1.53) 1.79 (1.03–3.12)a
Co-morbiditiesc
Moderate-to-severe liver disease 22/56 (39) 2.19 (1.25–3.85)a 2.82 (1.43–5.59)a
Metastatic cancer 27/65 (42) 2.46 (1.46–4.15)b 3.52 (1.87–6.61)b
Leukaemia 6/12 (50) 3.25 (1.04–10.19)a NS
Lymphoma 9/17 (53) 3.70 (1.41–9.73)a 8.78 (2.90–26.59)b
Chronic renal failure 85/264 (32) 1.90 (1.37–2.65)b 1.92 (1.28–2.88)a
Connective tissue disease 21/50 (42) 2.46 (1.37–4.42)a 2.38 (1.20–4.68)a
Type of infection
Pneumonia 42/96 (44) 3.52 (2.24–5.54)b 3.35 (1.96–5.73)b
Endocarditis 34/90 (38) 2.75 (1.71–4.41)b 2.89 (1.67–5.01)b
Unknown 10/27 (37) 2.66 (1.19–5.97)a 1.84 (0.65–5.17)
Other 109/602 (18) 1.00 1.00
Antibiotic susceptibility
Methicillin-susceptible 172/746 (23) 1.00 1.00
Methicillin-resistant 23/69 (33) 1.67 (0.98–2.83) 2.21 (0.99–4.96)
Effective treatment in ﬁrst 24 h
Methicillin-susceptible
Yes 131/575 (23) 1.00 NS
No 41/171 (24) 1.07 (0.72–1.60)
Methicillin-resistant
Yes 9/33 (27) 1.00 NS
No 14/36 (39) 1.70 (0.61–4.70)
Main treatment, ﬁrst 14 days
Cloxacillin 77/345 (22) 1.00 1.00
Cefazolin 20/133 (15) 0.62 (0.36–1.06) 0.65 (0.35–1.19)
Vancomycin 26/102 (25) 1.19 (0.71–1.99) 0.80 (0.38–1.70)
Other antibiotic 26/105 (25) 1.15 (0.69–1.91) 0.83 (0.46–1.53)
Multiple antibiotics 31/114 (27) 1.30 (0.80–2.11) 1.23 (0.70–2.17)
No antibiotic 15/16 (94) 52.2 (6.8–401.5)b 81.6 (9.2–724.2)b
NS, not signiﬁcant.
ap <0.05.
bp £0.001.
cFor these variables, the reference group varied and corresponded to those patients who did not have a speciﬁc co-morbidity.
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MSSA bacteraemia remains controversial. A
meta-analysis of 31 studies published before the
year 2000 suggested a higher mortality rate for
MRSA (pooled OR 1.9) [10], but there was signif-
icant heterogeneity. Only 11 studies had adjusted
for confounding factors, but their pooled OR of
1.9 was similar to that of the 20 studies without
adjustment (OR 1.7) [10], despite MRSA infec-
tions being typically associated with older age
and co-morbidities [11–14]. More recent studies
have provided contradictory results. Methicillin
resistance was associated with higher mortality
among Korean patients with SAB originating
from ‘non-eradicable infection’ (e.g., pneumonia,
endocarditis) [15]; a similar trend was noted in
the UK, but not the USA [12,16,17]. Among
patients with ventilator-associated S. aureus pneu-
monia, MRSA was not associated with a higher
mortality rate after adjustment for confounders
[18,19]. A prospective study of S. aureus endocar-
ditis revealed that MRSA was associated with a
longer duration of bacteraemia, which was itself
associated with mortality [20]. Some studies that
revealed no association between methicillin resis-
tance and mortality were methodologically
ﬂawed because they adjusted for shock [13,21]
or a high APACHE score [14,22], which are
variables that are intermediate steps in the causal
pathway between exposure and outcome. In the
present study, the association between methicillin
resistance and mortality was confounded essen-
tially by the period of diagnosis, and not by the
other independent correlates of mortality. The
difference in mortality rates between MRSA and
MSSA occurred during 2003–2005, at which time
there was a drop in mortality among patients with
MSSA bacteraemia.
The rise in mortality between 1991 and 2002 can
be attributed partially to secular changes in the
distribution of sources of SAB; thus, while the
contribution of catheter infections decreased dra-
matically, that of endocarditis or pneumonia
increased. During 2003–2005, the mortality rate
dropped sharply, while the age distribution and
the proportion of endocarditis and pneumonia
cases remained stable. The subgroup analyses did
not suggest that this was a consequence of better
management of sepsis, as the lower mortality rate
was seen in patients with and without shock
(activated protein C was given to only two
patients). The reduction in mortality occurred
essentially among patients with hospital-acquired
MSSA bacteraemia. Secular changes in the char-
acteristics of S. aureus isolates associated with
bacteraemia have been documented previously,
as determined by phage typing and antibiotic
susceptibility tests [23]. Variations in virulence
have been suggested as a possible mechanism
underlying profound geographical variations in
mortality in patients with S. aureus endocarditis
[24], and would be more plausible with MSSA
than MRSA, given the much higher clonal diver-
sity of the former [25]. Molecular studies are
needed to investigate potential changes over time
in virulence factors of S. aureus. Unfortunately,
the S. aureus isolates in the present study were not
retained. If MSSA virulence does indeed vary
over time and according to location, this may
contribute to the inconsistencies among published
studies concerning the putative higher mortality
rates for MRSA vs. MSSA.
Few studies have measured the population-
based incidence of SAB over long periods. In
Finland, where MRSA is uncommon, the inci-
dence of SAB rose from 11 to 17/100 000
between 1995 and 2001 [26]. In the UK, the
nationwide incidence of SAB more than doubled
(to 21/100 000) between 1993 and 2002 because
of a rising incidence of MRSA bacteraemia,
which did not replace, but added to, an un-
changed incidence of MSSA bacteraemia [4]. As
in a recent study in Oxfordshire, UK [17], the
incidence of MSSA bacteraemia did not change
in the present study (with the modest increase
being explained by the ageing population),
despite the appearance of MRSA in 2000. Thus,
MRSA has its own dynamics, presumably driven
by the use of antibiotics to which it is resistant,
especially the ﬂuoroquinolones [27], rather than
competing with MSSA for the same ecological
niche.
Table 4. Annual incidence of Staphylococcus aureus bacter-
aemia/100 000 inhabitants in Sherbrooke, Quebec, Can-
ada, during 1997–2005
1997–1999 2000–2002 2003–2005
Age, years
18–64 9.7 10.5 14.7
65–74 82.2 100.7 121.6
‡75 118.4 116.5 122.8
All 24.1 26.3 32.4
Acquisition
Hospital/healthcare 18.7 22.5 27.3
Community 5.4 3.8 5.1
Antibiotic susceptibility
Methicillin-susceptible 24.1 23.7 25.0
Methicillin-resistant 0 2.6 7.4
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The preponderance of males among patients
with SAB has been universal and remains unex-
plained; some studies, including the present
study, have shown a higher mortality rate among
women, while others have not [11–13,15,21,22,26].
The higher mortality among patients living out-
side the city of Sherbrooke presumably reﬂects
the selection process inherent to transfers of
patients between institutions. Age and high
Charlson scores are associated consistently
with mortality among patients with SAB
[11,12,21,22,26]. Among the speciﬁc medical con-
ditions associated with mortality, some presum-
ably reﬂect an impaired immune response to
S. aureus (e.g., lymphoma, connective tissue dis-
ease), while others might reﬂect a less aggressive
therapeutic approach (e.g., in cases of metastatic
cancer) or sub-optimal dosing of antimicrobial
agents (e.g., in cases of chronic renal failure).
The present ﬁndings agree with previous stud-
ies that have revealed higher mortality rates (35–
64%) among patients with bacteraemic S. aureus
pneumonia than among patients with S. aureus
endocarditis [12,14,18,20,22,23,28]. This ﬁnding
underlines the necessity of developing novel
therapeutic regimens for bacteraemic S. aureus
pneumonia, e.g., investigating whether adding
rifampicin for synergism might improve the
outcome, and examining in adequately powered
trials whether linezolid is superior to vancomycin
in pneumonia caused by MRSA, or even MSSA
[29]. Linezolid has better lung penetration than
vancomycin, with a much lower degree of pro-
tein-binding than oxacillin and cefazolin.
The present study had several limitations. First,
its retrospective nature meant that identiﬁcation
of the sources of bacteraemia depended on the
clinicians’ judgement, and the accuracy of diag-
noses may have changed over time, e.g., with the
identiﬁcation of endocarditis through a more
systematic use of trans-oesophageal echocardiog-
raphy. Second, the scarcity of MRSA reduced the
power of the study in making comparisons with
MSSA. Third, hospital mergers in 1996 might
have led to changes in the patient population,
perhaps in unmeasured characteristics (e.g., the
reasons leading to transfer of cases from other
hospitals) that resulted in residual confounding.
Nevertheless, in this well-deﬁned Canadian pop-
ulation, the emergence of MRSA led to an increase
in the overall incidence of SAB, with MRSA
adding to, rather than replacing, MSSA. The
mortality rate associated with S. aureus bacterae-
mic pneumoniawas as high as that associatedwith
endocarditis, and novel therapeutic approaches
are needed. Over the 15-year period of the study,
there were important changes, not only in the
sources of SAB, but also in the mortality rates
associated with nosocomial MSSA bacteraemia.
Whether this reﬂects changes in the virulence of
these organisms requires further investigation.
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